Sodium glucose cotransporter-2 (SGLT2) inhibitors

Where the papers sit

48 papers from the last 6 months study Sodium glucose cotransporter-2 (SGLT2) inhibitors directly · updated from PubMed 12 Oct 2026

• Diabetic Kidney Protection

  SGLT2 inhibitors are being positioned as kidney-protective therapy across type 2 diabetes, chronic kidney disease and end-stage kidney disease. Target-trial emulation and real-world cohorts assess renal, cardiovascular and blood-pressure outcomes, including in older adults and dialysis populations. Comparisons with semaglutide and GLP-1 receptor agonists are expanding toward combination treatment. Persistent prescribing gaps, nephrotoxic medication burden and tolerability still limit implementation.

  23 papers · 47.9%

• GLP-1 and SGLT2 Treatment

  Diabetes care is increasingly comparing GLP-1 receptor agonists with SGLT2 inhibitors across cardiovascular, renal, cognitive and cancer outcomes. Real-world studies also examine combination therapy, insulin initiation and treatment patterns. Cost, availability, affordability and managed-care return on investment are becoming central to treatment choice. The evidence remains outcome-specific rather than establishing one class as broadly superior.

  10 papers · 20.8%

• SGLT2 in Heart Failure

  Heart failure care is moving toward SGLT2 inhibitor use across preserved and reduced ejection fractions, with prevention also gaining attention in type 2 diabetes. Implementation studies emphasize uptake across the full ejection-fraction range. Dapagliflozin is examined with statins and sacubitril-valsartan, while empagliflozin is evaluated in preserved ejection fraction after aortic-valve intervention. Precision prescribing and obesity-related risk remain open questions.

  6 papers · 12.5%

• SGLT2 Safety and Persistence

  SGLT2 treatment is being judged increasingly by persistence and adverse-event risk alongside cardiovascular benefit. Hospitalisation is linked to treatment discontinuation, while sustained use in older adults is associated with cardiovascular outcomes. Urinary and genital infections, euglycaemic and diabetic ketoacidosis, pancreatitis and comparative safety with DPP-4 and GLP-1 therapies recur across the evidence. How to preserve long-term use while managing these risks remains unresolved.

  6 papers · 12.5%

• Others — SGLT2-Linked Molecular and Clinical Outcomes

  SGLT2-linked research here spans inflammatory and vascular kidney markers in youth with type 1 diabetes, molecular pathways relevant to heart-failure pacing response, and prognosis in diabetic patients with advanced lung cancer. The studies address different diseases, endpoints and biological levels. No shared mechanism, treatment strategy or clinical direction connects them beyond diabetes-related metabolic context. Their common ground is therefore limited to exploratory SGLT2-associated outcomes.

  3 papers · 6.2%